NAD+ Therapy for Improving Memory & Cerebrovasular Function in Patients with MCI

项目摘要 候选人：克里斯托弗·R。Martens博士，是该大学综合生理学的博士后研究员 位于科罗拉多博尔德。在这个K 01应用中，Martens博士的目标是研究一种新的NAD+增强的功效。 和模拟热量限制的化合物烟酰胺核苷（NR），用于改善记忆， 遗忘型轻度认知障碍（aMCI）老年人的脑血管功能。他的近期目标是 获得必要的研究培训和专业技能，从博士后过渡到 独立的学术研究者。他的长期目标是建立自己的校外资助研究 计划，主要侧重于确定治疗脑血管功能障碍的治疗策略， 改善认知功能，降低老年人患阿尔茨海默病（AD）的风险。职业生涯 发展计划：Martens博士建议通过以下方式加强其职业发展：1）获得新的 认知和脑血管功能评估的实验技能，以支持他的建议 研究计划; 2）接受MCI和AD病理生理学，老年医学和生物统计学的进一步培训;以及3） 完善他的专业技能发展，包括正式课程的工作，出席和演示， 每周期刊俱乐部，大学研讨会，国家科学会议，神经病学和老年学大 轮系列，并通过与他的指导团队定期互动。环境：马滕斯博士将训练 在一个出色的环境中，由多学科的导师团队提供支持， 研究和职业发展培训。主要导师Seals博士是国际公认的， 国家情报局资助的科学家，在与衰老有关的生物医学研究方面有着成功的指导记录， 血管功能障碍共同导师休森博士是脑血管疾病评估领域的领先专家 功能和大脑老化，Bettcher博士在评估患者的认知功能方面拥有丰富的经验 关于MCI McQueen博士是CU-Boulder临床和转化研究中心的生物统计学主任 （CTRC），并拥有为学员和教职员工提供指导和咨询的丰富经验 进行临床试验。Potter博士和Schwartz博士是NIA的高级调查员， 老年痴呆症和老年医学，分别，并将提供导师，以补充 研究培训和目标。指导小组将在拟议的 研究项目和总体培训计划。研究：aMCI是最早的症状阶段， AD是美国增长最快的死亡原因之一。aMCI与 脑血管功能受损，可能导致认知障碍并导致风险增加 AD相关的痴呆症这项拟议中的研究旨在测试一种新型的CR模拟饮食的功效， 补充剂NR，用于改善aMCI老年人的记忆和脑血管功能。结果 本研究将提供对预防或延迟AD的潜在有益疗法的功效的深入了解。

PROJECT SUMMARY CANDIDATE: Christopher R. Martens, Ph.D., is a postdoctoral fellow in Integrative Physiology at the University of Colorado Boulder. In this K01 application, Dr. Martens aims to study the efficacy of a novel NAD+ boosting and calorie restriction-mimetic compound, nicotinamide riboside (NR), for improving memory and cerebrovascular function in older adults with amnestic mild cognitive impairment (aMCI). His immediate goal is to acquire the research training and professional skills necessary to transition from a postdoctoral fellow to an independent academic investigator. His long-term goal is to establish his own extramurally funded research program, with a primary focus on identifying therapeutic strategies for treating cerebrovascular dysfunction, improving cognitive function and reducing the risk Alzheimer's disease (AD) in older adults. CAREER DEVELOPMENT PLAN: Dr. Martens proposes to enhance his career development by: 1) acquiring new experimental skills in the assessment of cognitive and cerebrovascular function to support his proposed research plan; 2) receiving further training in MCI and AD pathophysiology, geriatrics and biostatistics; and 3) refining his professional skills development including formal course work, attendance and presentations at weekly journal clubs, university seminars, national scientific meetings, and Neurology and Geriatric Grand Round Series, and through regular interactions with his mentoring team. ENVIRONMENT: Dr. Martens will train in an outstanding environment supported by a multi-disciplinary team of mentors who will provide him with research and career development training. The principal mentor, Dr. Seals, is an internationally recognized and NIA-funded scientist with a strong record of successful mentoring in biomedical research pertaining to aging and vascular dysfunction. Co-Mentor Dr. Hughson is a leading expert in the assessment of cerebrovascular function and brain aging, and Dr. Bettcher is has extensive experience assessing cognitive function in patients with MCI. Dr. McQueen is director of biostatistics at the CU-Boulder Clinical and Translational Research Center (CTRC) and has extensive experience providing mentoring and consulting to trainees and faculty members conducting clinical trials. Co-mentors Dr. Potter and Dr. Schwartz are senior NIA investigators with expertise in Alzheimer's disease and geriatric medicine, respectively, and will provide mentorship to complement the research training & objectives. The mentorship team will provide specific expertise in key areas of the proposed research project and overall training plan. RESEARCH: aMCI is the earliest symptomatic stage in the development of AD, which is among the fastest growing causes of death in the US. aMCI is associated with impaired cerebrovascular function, which likely contributes to cognitive impairment and leads to increased risk of AD-related dementia. The proposed research seeks to test the efficacy a novel CR-mimicking dietary supplement, NR, for improving memory and cerebrovascular function in older adults with aMCI. Results from this study will provide insight into the efficacy of a potential beneficial therapy for preventing or delaying AD.